Top Natural Language Processing Companies in NYC, NY (75)

Product Line Growth: The product footprint is expanding, with S&P highlighting Kensho Link and the LLM‑ready API while Kensho adds datasets like private‑company financials and Capital IQ Estimates plus integrations with Anthropic, ChatGPT, Amazon Quick Suite, and Databricks. This indicates broader functionality and distribution across enterprise AI workflows.

Strategic Partnerships: Enterprise collaborations are scaling, exemplified by RBC Capital Markets integrating Kensho/S&P Global data to 8,000 employees and reported ties into ecosystems such as Cohere and MCP-enabled chat interfaces. These relationships suggest growing commercial reach through key institutional channels.

Future-Ready Strategy: S&P Global’s July 2026 reorganization established Kensho Data & Platforms as the client-facing data-product and AI-delivery layer, positioning the business to accelerate AI-powered products. This structural elevation signals commitment to AI-led growth across S&P’s portfolio.

Strong Revenue Growth: Revenue momentum is described as rapid, with the company citing 15× growth over 18 months and coverage noting roughly $13M ARR in mid-2024. Independent estimates indicate ARR scaling into the tens of millions through 2025–2026, suggesting continued top-line expansion despite the absence of audited figures.

Investor Backing & Capital Strength: A sizable $130M Series B in 2024 led by Andreessen Horowitz, bringing total funding to roughly $161M alongside a reported ~$700M valuation, signals strong capital support. This investor base and funding depth provide capacity to invest in product and go-to-market.

Market Expansion: Geographic and product scope have broadened, including expansion into the UK and Europe and additions such as agents, research capabilities, and financial-data integrations. Company-reported activity—hundreds of thousands of daily prompts, billions of pages processed, and 1,000+ use cases across finance, legal, banking, and corporate finance—points to widening reach.

Strong Revenue Growth: ARR is reported to have surpassed $200M by June 2026 after crossing $100M in early 2025, with five consecutive years of 100% year-over-year growth. This consistent doubling signals rapid scaling at substantial revenue levels.

Investor Backing & Capital Strength: Funding rounds include $75M in 2024 at a valuation above $1B and a $250M Series E in 2025 at a reported $2.2B, with total capital raised cited at $400M+. Such late-stage financing and rising valuations indicate robust access to growth capital.

Strong Market Position & Advantage: Adoption is described as reaching roughly 1 in 6 U.S. apartments, with deep penetration among large property managers and hundreds of operators. Expansion into healthcare and notable distribution relationships have broadened its commercial footprint.

Investor Backing & Capital Strength: Strategic capital is substantial, with $1B raised in 2025 to fund expansion into an AI productivity platform. This provides significant financial capacity for acquisitions and product development.

Product Line Growth: The company has broadened its footprint through acquisitions including Coda (now part of the suite), GPTZero, Rows, and Fathom, while integrating advanced AI capabilities like Superhuman Go and agent ecosystems. These moves expand the offering well beyond the original email client.

Market Expansion: Current materials cite 40M+ daily active users and 50K+ organizations, reflecting the larger Superhuman/Grammarly platform after the rebrand. Continued M&A in 2026 further extends reach into authenticity and meeting-productivity use cases.

Investor Backing & Capital Strength: Investors have continued to back the company with significant new capital post‑spinout, including additional rounds that independent sources corroborate. This suggests a solid financial runway to support ongoing expansion.

Innovation-Driven Growth: The company has shifted firmly toward an AI‑native customer‑experience platform, highlighting sustained investment in agentic architecture and frequent AI product releases. This pattern indicates active product expansion rather than a stagnant portfolio.

Customer Loyalty & Retention: The customer base includes recognizable brands and examples of multi‑year usage, alongside reports of improved retention and faster renewals. These signals point to durable relationships and expanding adoption among existing accounts.

Strong Revenue Growth: Operating revenue increased meaningfully year over year while capacity also rose, signaling robust top-line momentum in tandem with expanding operations. Feedback suggests this growth has been sustained across consecutive fiscal periods.

Market Expansion: The network has broadened to 32 destinations with cumulative passengers surpassing 25 million, alongside added international routes and higher departures. These developments indicate widening reach and growing traffic throughput.

Future-Ready Strategy: Management outlines continued capacity growth over the next several years, supported by a large Boeing 737 MAX order pipeline. This long-horizon fleet plan underpins ongoing scale-up ambitions.

Product Line Growth: Growth across non‑COVID medicines such as Eliquis, Padcev, the Vyndaqel family, Lorbrena, Nurtec/Vydura and oncology biosimilars has been robust. Launched and acquired products are showing sustained double‑digit operational gains, adding meaningful momentum.

Resilient & Sustainable Growth: Excluding COVID products, the underlying portfolio delivered mid‑single‑digit operational growth in 2025 and continued at a similar pace in early 2026, more than offsetting part of the COVID‑related decline. Reported revenue also returned to modest year‑over‑year growth in the first half of 2026, indicating stabilization.

Future-Ready Strategy: Management raised the midpoint of 2026 revenue guidance and continues to invest heavily in a broad late‑stage pipeline. This posture signals confidence that newer launches and acquired assets can drive the next leg of growth.

Investor Backing & Capital Strength: Recent funding rounds totaling $65M, including a $45M Series B co-led by Lightspeed and QED in January 2026, provide resources to scale product and go-to-market. Company announcements state the capital will expand enterprise capabilities and team growth.

Strong Revenue Growth: An 8x year-over-year revenue growth figure is cited alongside rapid expansion from 1,000+ to 5,000+ firms using the platform. While audited figures are not public, multiple provided sources describe fast top-line momentum during 2025–2026.

Strategic Partnerships: Enterprise relationships and distribution with large advisor networks (e.g., Hightower exclusivity and availability to Cetera’s ~12,000 professionals) meaningfully expand reach. Ongoing integrations with platforms like Wealthbox, Redtail, Practifi, and Conquest reinforce ecosystem leverage.

Investor Backing & Capital Strength: Capital access is described as exceptional, with over $1B in total funding and a valuation rising to $5.3B across successive rounds backed by top‑tier and strategic investors. This depth of financing signals ample runway for R&D and go‑to‑market scale.

Strong Revenue Growth: Revenue momentum is highlighted by contracted ARR of $117M in early 2025 and estimates that actual ARR crossed $100M by mid‑2025, alongside a 4x increase over 18 months. These points indicate rapid monetization of enterprise deployments.

Market Expansion: Enterprise adoption expanded from roughly 100–150 health systems in early/mid‑2025 to more than 250–300 by mid‑2026, including large rollouts at Kaiser Permanente and other marquee systems. Scaling conversation volume from ~50M in 2025 to a projected 80M+ in 2026 underscores a widening footprint.

Strong Revenue Growth: Reported ARR advanced from $200M in 2024 to $400M and $500M in 2025 and surpassed $600M by mid-2026, evidencing rapid scaling. Consecutive milestones and increased enterprise adoption underpin momentum.

Investor Backing & Capital Strength: A $350M financing at a $7.5B valuation in June 2026, including strategic participation, signals strong investor confidence. Fresh capital supports continued product and go-to-market investment.

Strong Market Position & Advantage: Recognized as a Leader in Gartner’s 2026 Magic Quadrant for Competitive & Market Intelligence Platforms, with additional visibility across major industry lists and analyst evaluations. Broad enterprise penetration and premium content breadth reinforce positioning.